Models for 10,000 Human Diseases

Welcome to Part 4 of our series about the blood brain barrier (BBB)! Here, we highlight the rising global burden of neurological disorders, and recap on the challenges surrounding drug safety and toxicity in relation to the BBB. As industry speeds ahead with novel therapeutic approaches to neurological and non-neurological diseases, such as adeno-associated virus (AAV)-based gene therapies, CAR-T cell therapies, and gene-editing therapies, the need to understand safety and toxicity in relation to BBB penetration has never been more urgent.  According to a report published by the World Health Organization (WHO), up to one billion people worldwide were affected by a neurological...